Bicycle Therapeutics

Congrats to our CEO Kevin Lee! He received @BIA_UK's prestigious Entrepreneur of the Year award for his outstanding leadership and impact in the UK life sciences sector. Very proud of Kevin’s role in shaping the future of #biotech #innovation. More here: bit.ly/4aEU8oO.

Many thanks to @jpmorgan for inviting us to present at #JPM2025 about our work to develop #cancer medicines and our goal of helping patients live longer and live well. A replay of our presentation and Q&A session is available here: bit.ly/3WjQwCT.

We are a proud sponsor of @BladderCancerUS Walk to End #BladderCancer. From Boston to Seattle to Richmond, VA, to Cambridge, UK, we joined this powerful community to honor those who live with this disease every day. #BladderCancerAwarenessMonth

At #ASCO25, we look forward to presenting two posters about our Bicycle® Drug Conjugate zelenectide pevedotin and our Phase 2/3 Duravelo-2 trial for #bladdercancer. Stop by on Monday, June 2, at 9 a.m.-12 p.m. CT. More here: bit.ly/43IkLar.

Honored to host our Clinical Advisors @niklas_kluemper and @Markuseckstein3 and our collaborator @braegelmannlab at our UK office this week. As part of their visit, our team was treated to a deep-dive seminar on NECTIN4 gene amplification. #PrecisionOncology at its finest!

In honor of National #Cancer Research Month, we recognize the invaluable, lifesaving discoveries made by the #cancerresearch community. We are proud to contribute to scientific advancements in #oncology treatment and care. #UnitedByCancerResearch

Today at #AACR25, we are proud to present additional human #radiopharmaceuticals imaging data for an early Bicycle® Radioconjugate targeting MT1-MMP, a tumor antigen overexpressed in many #cancers. More info: bit.ly/42wvnZE

DYK: Bicycle molecules can be used to develop potential treatments for diseases affecting the skeletal muscle and heart? New preclinical data with our partner @ionispharma demonstrates the expansive potential of our Bicycle technology. More here: bit.ly/4jwUSzO

We are excited to announce new appointments to our Board of Directors & leadership team, including Felix Baker who will become our new chairman, Alessandro Riva who joins our Board and Fabrice Andre who joins our Clinical Advisory Board. Read more here: bit.ly/43YifNO

We are proud to share at #ELCC25 our NECTIN4 gene amplification data in non-small cell #lungcancer. Don’t miss our poster presentation on Friday at 1 p.m. CET, or head to the Publications section of our website for a copy of the poster. bit.ly/4ab2P9c

Our CEO Kevin Lee will share our #radiopharmaceuticals #research at the 2025 Transatlantic Exchange in #Oncology hosted by @DanaFarber & @GustaveRoussy. He will join world-leading #cancer experts as they discuss the latest advances in this area. More info: bit.ly/4kQY36B

Thanks @ChamberVoice for hosting us at your #InternationalWomensDay Reception. We were honored to join members of parliament to support the @5050Parliament movement & celebrate the significant leadership contributions women bring to every organization. #IWD2025 #AccelerateAction

Today at the TD Securities 45th Annual Health Care Conference, our management team discussed our progress advancing our R&D pipeline of targeted #cancer therapies and #radiopharmaceuticals, and the milestones we have planned for 2025. Replay here: bit.ly/4i0g4xJ.

Today we reported recent business progress and fourth quarter and full year 2024 financial results. Read our press release here: bit.ly/4bhSKsL.

Thanks to @Oppenheimer for hosting a fireside chat with our CFO Alethia Young at the 35th Annual #OPCOLifeSciences Conference. We have an exciting year ahead as we work to advance our pipeline of differentiated medicines for #cancer. Replay available here: bit.ly/3QdLcxt

#WorldCancerDay is a reminder to come together to take action against #cancer. United in our goals to improve the lives of those affected by cancer, we are working urgently to develop medicines that have the potential to help people live longer and live well.

Today, to kick off #JPM25, we announced updated topline data for our lead therapeutic candidate in #bladdercancer and highlighted our 2025 strategic priorities and milestones. Tune in to our #JPM2025 presentation tomorrow at 5:15 p.m. PT. More info here: bit.ly/3Wke2PZ.

From all of us at Bicycle Therapeutics, we wish everyone a heartwarming 2024 holiday season. This year we are proud to donate to @samaritans @ArthurRankHouse and @RosiesPlace, and provide gifts to children cared for by @Mass_DCF. Happy Holidays and Happy New Year!

Today during #SABCS24, we announced data updates for zelenectide pevedotin in #BreastCancer, #lung #cancer & #bladdercancer. Join our investor call tomorrow at 8 a.m. ET where we’ll review & discuss the data. Read more here: bit.ly/41wjLWv.

A warm welcome to the new members of our Clinical Advisory Board! We look forward to their insights and guidance as we work to develop our precision-targeted therapies for the benefit of #cancer patients around the world. bit.ly/41ywJ5M